Strides Pharma Q2 FY27 Earnings Call — Analysis (NSE: STAR)

Strides reported record quarterly revenue of ₹1,429.7 Cr (+17% YoY) as Ex-US surged 31% to surpass US revenue, while the $375M US revenue target was pushed out to FY29 due to normalised oral solid shortage opportunities.

2 Nov 2026 · Analysis by Alpha Inflection

Result quality: stable — Results context unavailable. Management sentiment: optimistic.

The take

Q2FY27 Revenue ₹1429.7 Cr ( +17% YoY ) . Guidance raised — FY28 ex-us revenue target $375 million . But missed — Profitability and margin discipline . New story: Ex-US acceleration and diversification .

Results

Revenue grew 17% YoY to ₹1,429.7 Cr with EBITDA at ₹250.9 Cr (+8% YoY) and EBITDA margin compressing 140 bps YoY to 17.6% due to elevated freight and geopolitical supply chain costs.

Financial highlights

Guidance

Management maintained its overall FY28 top-line growth ambition with Ex-US expected to exceed $375M by FY28, while deferring the $375M US aspiration timeline by 3-4 quarters to FY29.

What management committed to

• Ex-US business revenue will exceed $375 million in FY28. — $375 million, FY28
• The Sandoz acquisition will close in Q3 FY27. — FY27
• Quarterly finance cost will be in the INR 40-45 Crore range for H2 FY27. — INR 40-45 Crore, FY27
• The cash conversion cycle will normalize by Q3 FY27. — FY27
• The net debt-to-EBITDA ratio will stabilize and improve by the end of FY27. — FY27
• Strides will launch 4 to 6 products in the US in H2 FY27. — 4-6, FY27
• A controlled-substance transdermal patch will be relaunched in Q3 FY27. — FY27
• Differentiated products (nasal sprays, patches, films) will begin meaningful revenue contribution in FY28/FY29. — FY29

Key themes

Ex-US expansion and US pipeline diversification

How the narrative shifted

• US market evolution and cost normalization: Management presents the US revenue timeline delay as an industry-wide normalization and a deliberate choice to protect margins rather than a competitive failure.
• Ex-US acceleration and diversification: Ex-US has surpassed US revenue ahead of schedule, establishing the company as a diversified two-engine growth story with accelerating momentum in UK, Europe, Nordics, and Africa.
• Geopolitical cost headwinds on margins: Management frames the margin compression as temporary and expects H1 gross margins (58.3%) to be sustainable going forward.
• Profitability and margin discipline: Management elevates this to a core explanatory principle for both the US timeline shift and the selective launch strategy.
• Controlled Substances and differentiated pipeline: A multi-platform CS pipeline (nasal sprays, patches, films) addresses a $4.5B market, requires limited API quota, and leverages the US manufacturing facility as a structural competitive advantage.
• Working capital normalization: Management attributes the debt increase to temporary geopolitical stockpiling and reaffirms the long-term net debt aspiration despite the near-term pressure.
• Sandoz acquisition regulatory timeline: The Sandoz deal is progressing but delayed by outstanding antitrust approvals in a few countries, pushing the close from Q2 to Q3 FY27.

Operational commentary

• Ex-US revenue surpassed US revenue in Q2 FY27 (reaching 102% of US revenue), achieving the rebalancing target ahead of the FY28 timeline.
• US market dynamics shifted as oral solid shortage opportunities normalised; company prioritised profitability discipline over low-margin volume chasing.
• Chestnut Ridge US facility operationalised for Controlled Substances (CS); active pipeline includes >10 CS products spanning nasal sprays, patches, and films addressing a $4.5B market.
• Filed third nasal spray (controlled substance) in September 2026; first nasal spray has GDUFA goal date in H2 FY27 with approval anticipated in Q4 FY27.
• Transdermal patch acquired from Endo scheduled for relaunch in Q3 FY27, with full-year revenue benefit expected in FY28.
• Sandoz transaction in Francophone Africa awaiting antitrust approval in a few remaining countries; expected to close in Q3 FY27.
• Commercialised US portfolio expanded to 75 products with 3 new launches during Q2; company holds top-three market positions in 38 products contributing ~70% of US revenue.
• Added Mr. Biren Gabhawala as Independent Director, raising independent board representation to 6 out of 10 directors.

Analyst Q&A

• Q. What is driving non-US momentum and what growth is expected over the next 2-3 years including Sandoz?

  Growth is broad-based across B2B and B2C markets with high stickiness and expansion into new territories; Ex-US will grow faster than the company average and exceed $375M by FY28, with Sandoz providing meaningful scale upon closing.

• Q. Why did US revenue remain flat YoY in dollar terms ($73M)?

  Driven by product mix and pricing adjustments alongside deliberate forfeiture of low-margin volumes where oral drug shortages normalised, maintaining strict profitability thresholds.

• Q. What is the reason for the debt increase and is the debt-free timeline pushed back?

  The ₹211 Cr debt increase in H1 was entirely driven by working capital (₹174 Cr inventory build for supply chain buffers); as inventory normalises in H2, cash flow conversion will resume and long-term deleveraging trajectory remains intact.

• Q. Why did gross margin slip sequentially to 56% and what gives confidence for H2 recovery?

  Q2 consumed high-cost inventory procured during peak geopolitical disruptions; cost improvement programmes and alternate sourcing are already yielding internal results, supporting ~58% gross margins in H2.

View source

Research and educational content only. Not investment advice.